Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration
Luis Arias1,2, Jordi Monés11Institut de la Màcula i de la Retina, Centro Médico Teknon, Barcelona; 2Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, BarcelonaPurpose: To determine the efficacy and safety of treating predominant...
Guardado en:
Autores principales: | Luis Arias, Jordi Monés |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b7d3fceb56d244fea27dc88ec79a3637 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Learning curve of sutureless transconjunctival 20-gauge vitrectomy
por: Simanjuntak GWS, et al.
Publicado: (2014) -
Bacterial endophthalmitis following 25-gauge transconjunctival sutureless vitrectomy
por: Drew N Sommerville, et al.
Publicado: (2008) -
Sympathetic ophthalmia after 23-gauge transconjunctival sutureless vitrectomy
por: Masatoshi Haruta, et al.
Publicado: (2010) -
Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
por: Kumagai K, et al.
Publicado: (2019) -
Outcome of 20-gauge transconjunctival cannulated sutureless vitrectomy using silicone oil or air tamponade
por: Mohamed AA, et al.
Publicado: (2013)